Valion Bio Opens San Antonio Biomanufacturing Plant with 45 Staff Supporting Entolimod
Valion Bio opened its wholly owned Velocity Bioworks biomanufacturing facility at the VelocityTX campus in San Antonio with 45 employees and completed tech transfer for GMP-scale production of its lead asset Entolimod. This end-to-end domestic plant positions the company for Strategic National Stockpile, oncology supportive care and third-party CDMO clients.
1. Facility Launch and Capacity
On May 6, 2026 Valion Bio activated its wholly owned Velocity Bioworks biomanufacturing facility on the VelocityTX campus in San Antonio, Texas. The site employs around 45 scientists, engineers and operators and has completed tech transfer and incremental scale-up for GMP production of Entolimod.
2. Vertical Integration Strategy
The new plant represents the formal activation of Valion Bio’s vertical integration approach, securing end-to-end domestic control over its lead asset manufacturing. Leadership highlighted the importance of a secure U.S. supply chain for national preparedness and oncology supportive care programs.
3. Entolimod Manufacturing and Applications
Entolimod, a TLR5 agonist, is being developed for acute radiation syndrome under the FDA Animal Rule pathway and for chemotherapy-induced neutropenia in oncology supportive care. The facility’s capabilities align with potential BARDA and Strategic National Stockpile commitments.
4. CDMO Offering and Regional Partnerships
Velocity Bioworks is set to serve as a contract development and manufacturing organization for third-party biologics clients, leveraging San Antonio’s life-sciences talent, military medical research presence and strategic logistics infrastructure. The location’s proximity to Joint Base San Antonio supports rapid nationwide deployment of medical countermeasures.